Curespec is transforming the treatment of chronic kidney disease and hypertension—conditions affecting over 700 million people worldwide.

Our proprietary Electro-Hydraulic Acoustic Therapy (eHAT), a CE-marked and non-invasive solution, is designed to rejuvenate renal tissue, improve kidney function, and reduce blood pressure with lasting clinical benefits.

Clinical data shows that 90% of patients either maintain their eGFR levels or achieve a reduction of at least 5 mmHg in blood pressure.

With an estimated $16.7 billion addressable market across the U.S. and Europe, Curespec is leading a new paradigm in the management of kidney and cardiovascular health.

Join us in our mission to improve patient outcomes and redefine the future of healthcare.